MARK4

Across TCGA pan-cancer cohorts, MARK4 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MARK4’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MARK4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MARK4 is over-expressed in tumor.

HNSC, KIRC, and KIRP are the cancer types where MARK4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MARK4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.887	<.001	11	view →
KIRC	Female	All	+0.650	<.001	11	view →
KIRP	All	III,IV	+0.567	.001	10	view →
COAD	Female	II,III,IV	+0.480	<.001	10	view →
LIHC	Female	II,III,IV	+1.788	<.001	9	view →
LUSC	Female	All	+0.817	<.001	8	view →
BRCA	All	II,III,IV	+0.365	<.001	8	view →
LUAD	All	III,IV	+0.563	.002	6	view →
CHOL	Female	All	+2.110	<.001	5	view →
STAD	All	II,III,IV	+0.677	.006	4	view →
PAAD	Male	All	+0.310	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MARK4–HNSC

Open the HNSC breakdown →